ENTPD1 and metabolic dysfunction-associated steatohepatitis: These results suggest that other cell type/s might be responsible for ENTPD1 expression in livers with NASH, or, more likely, that the treatment of human primary KC and CD14+ monocytes require different times and/or concentrations of LPS and ATP treatment to potentially induce ENTPD1.